Abstract
Sickle cell disease refers to a group of inherited hemoglobinopathies characterized by abnormal hemoglobin genes. The resulting abnormal hemoglobin protein results in sickling of erythrocytes, intravascular hemolysis, defective oxygen transport, and tissue damage due to ischemia and necrosis. Sickle cell disease manifests systemically in many organs such as the brain, lungs, heart, liver, spleen, kidneys, joints, bones, and skin (Yawn et al. 2014).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alam M, Thapa D, Lim JI, et al. Quantitative characteristics of sickle cell retinopathy in optical coherence tomography angiography. Biomed Opt Express. 2017;8:1741–53.
Chen RWS, Flynn HW, Lee W-H, et al. Vitreoretinal management and surgical outcomes in proliferative sickle retinopathy: a case series. Am J Ophthalmol. 2014;157:870–5.e1.
Cho M, Kiss S. Detection and monitoring of sickle cell retinopathy using ultra wide-field color photography and fluorescein angiography. Retina. 2011;31:738–47.
Chow CC, Genead MA, Anastasakis A, et al. Structural and functional correlation in sickle cell retinopathy using spectral-domain optical coherence tomography and scanning laser ophthalmoscope microperimetry. Am J Ophthalmol. 2011;152:704–11.e2.
Chow CC, Shah RJ, Lim JI, et al. Peripapillary retinal nerve fiber layer thickness in sickle-cell hemoglobinopathies using spectral-domain optical coherence tomography. Am J Ophthalmol. 2013;155:456–64.e2.
Condon PI, Serjeant GR. Behaviour of untreated proliferative sickle retinopathy. Br J Ophthalmol. 1980;64:404–11.
Estepp JH, Smeltzer MP, Wang WC, et al. Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children. Br J Haematol. 2013;161:402–5.
Fox PD, Dunn DT, Morris JS, Serjeant GR. Risk factors for proliferative sickle retinopathy. Br J Ophthalmol. 1990;74:172–6.
Ghasemi Falavarjani K, Scott AW, Wang K, et al. Correlation of multimodal imaging in sickle cell retinopathy. Retina. 2016;36(Suppl 1):S111–7.
Gill HS, Lam W-C. A screening strategy for the detection of sickle cell retinopathy in pediatric patients. Can J Ophthalmol. 2008;43:188–91.
Goldberg MF. Retinal neovascularization in sickle cell retinopathy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;83:OP409–31.
Grover S, Sambhav K, Chalam KV. Capillary nonperfusion by novel technology of OCT angiography in a patient with sickle cell disease with normal fluorescein angiogram. Eur J Ophthalmol. 2016;26:e121–3.
Hayes RJ, Condon PI, Serjeant GR. Haematological factors associated with proliferative retinopathy in homozygous sickle cell disease. Br J Ophthalmol. 1981;65:29–35.
Hoang QV, Chau FY, Shahidi M, Lim JI. Central macular splaying and outer retinal thinning in asymptomatic sickle cell patients by spectral-domain optical coherence tomography. Am J Ophthalmol. 2011;151:990–4.e1.
Lim JI. Ophthalmic manifestations of sickle cell disease: update of the latest findings. Curr Opin Ophthalmol. 2012;23:533–6.
Lim JI, Cao D. Analysis of retinal thinning using spectral-domain optical coherence tomography imaging of sickle cell retinopathy eyes compared to age- and race-matched control eyes. Am J Ophthalmol. 2018;192:229–38.
Mitropoulos PG, Chatziralli IP, Parikakis EA, et al. Intravitreal ranibizumab for stage IV proliferative sickle cell retinopathy: a first case report. Case Rep Ophthalmol Med. 2014;2014:682583.
Moshiri A, Ha NK, Ko FS, Scott AW. Bevacizumab PRESURGICAL treatment for proliferative sickle-cell retinopathy-related retinal detachment. Retin Cases Brief Rep. 2013;7:204–5.
Paton D. Angiod streaks and sickle cell anemia: a report of two cases. Arch Ophthalmol. 1959;62:852–8.
Romayanada N, Goldberg MF, Green WR. Histopathology of sickle cell retinopathy. Trans Am Acad Ophthalmol Otolaryngol. 1973;77:OP642–76.
Ryan SJ, Goldberg MF. Anterior segment ischemia following scleral buckling in sickle cell hemoglobinopathy. Am J Ophthalmol. 1971;72:35–50.
Shaikh S. Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy. Indian J Ophthalmol. 2008;56:259.
Siqueira RC, Costa RA, Scott IU, et al. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol Scand. 2006;84:834–5.
Walton W, Von Hagen S, Grigorian R, Zarbin M. Management of traumatic hyphema. Surv Ophthalmol. 2002;47:297–334.
Williamson TH, Rajput R, Laidlaw DAH, Mokete B. Vitreoretinal management of the complications of sickle cell retinopathy by observation or pars plana vitrectomy. Eye. 2009;23:1314–20.
Witkin AJ. Optical coherence tomography demonstration of macular infarction in sickle cell retinopathy. Arch Ophthalmol. 2006;124:746.
Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033–48.
Acknowledgments
The authors would like to thank Mark Janowicz, Principal Ophthalmic Photographer at Illinois Eye and Ear Infirmary, University of Illinois at Chicago, for his expertise with the acquisition of images in this chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Chee, Ri., Zahid, S., Lim, J.I. (2020). Sickle Cell Retinopathy. In: Sheyman, A., Fawzi, A.A. (eds) Retinal Vascular Disease. Retina Atlas. Springer, Singapore. https://doi.org/10.1007/978-981-15-4075-2_14
Download citation
DOI: https://doi.org/10.1007/978-981-15-4075-2_14
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-4074-5
Online ISBN: 978-981-15-4075-2
eBook Packages: MedicineMedicine (R0)